Navigation Links
Telik Announces Financial Results for 2008 Third Quarter
Date:11/5/2008

Research and development expenses for the quarter ended September 30, 2008 were $4.8 million, compared to $8.2 million in the second quarter of 2008 and $9.4 million for the third quarter in 2007. General and administrative expenses for the quarter ended September 30, 2008 were $2.8 million, compared to $2.8 million in the prior quarter and $3.7 million for the comparable period in 2007.

For the nine months ended September 30, 2008, Telik reported a net loss of $31.4 million, or $0.59 per share, compared with a net loss of $42.3 million, or $0.81 per share, for the nine months ended September 30, 2007. Total operating expenses for the first nine months of 2008 were $29.5 million, compared with $46.8 million for the first nine months of 2007. Operating expenses in the first nine months of 2008 included approximately $4.9 million in stock-based compensation expense. The reduction in operating expenses of approximately 37% in the first nine months of 2008 compared with the same period in 2007 was primarily due to reduced clinical trial and related expenses, lower headcount and administrative expenses as well as lower stock-based compensation expense.

Conference Call and Webcast

Telik will conduct its quarterly conference call today at 4:30 p.m. Eastern time (1:30 pm. Pacific time). The conference call will be accessible via Telik's website at http://www.telik.com or by telephone at 800-398-9367 or 612-332-7517. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 966597. The archive will be available from approximately 6:30 p.m. Eastern time on November 5 through November 19, 2008.

About Telik

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational dr
'/>"/>

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
2. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
3. Telik Announces Receipt of Nasdaq Notice
4. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
5. ReceptorBio Announces Diabetes License Agreement With Telik
6. Telik Announces Financial Results For 2008 Second Quarter
7. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
8. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
9. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
10. Telik Announces First Quarter 2008 Financial Results
11. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... An international research team including DESY scientists has observed ... The team reports in the journal Science ... lattices inside the nanodroplets. It is the first time ... in larger samples of what is known as superfluid ... exceeded our best expectations," says Andrey Vilesov of the ...
(Date:8/21/2014)... 21, 2014 His Majesty Willem-Alexander, King ... The Court of His Majesty Willem-Alexander, King of the ... Grand Opening of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ... , The King will take part in the Grand ... for 11 a.m.-12:20 p.m. and tour the plant. POET-DSM ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources Group ... Brazil and Mexico ... of several newly approved agents, the anticipated label ... and the launch of emerging biologics will substantially ... particular, the emerging IL-5 inhibitors will introduce a ...
(Date:8/21/2014)... KONG , Aug. 21, 2014  China Cord Blood ... announced its plan to release financial results for the ... 28, 2014, after market close in the US.  ... at 8:00 a.m. ET on Friday, August 29, 2014 ... overview of the Company,s recent developments, followed by a ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2
... increasing global demand for health ... economics and market access support, BOSTON, Oct. ... Adam Barak as Vice President., Mr. Barak brings 16 ... pricing and reimbursement strategies,for drugs, medical devices, and diagnostics in ...
... Also Announces Completion of Enrollment in U.S. Phase ... Hepatitis C,Genotype 1, TAMPA, Fla., Oct. 28 ... announced the presentation of studies,of nitazoxanide at the ... the Study of Liver Diseases (AASLD), also known ...
... - Laureate To Manufacture Tolera,s Monoclonal Antibody ... 28 Laureate Pharma, Inc., a,full-service biopharmaceutical ... it has entered into a cGMP contract ... company that,develops and offers targeted therapies and ...
Cached Biology Technology:Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability 2Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc. 2
(Date:8/22/2014)... presented at the 29th Annual International Papillomavirus Conference ... Therapeutics Inc. combats three types of human papillomavirus, ... all cervical cancer. , When tested in several ... of HPV-16, HPV-18 and HPV-11 cells, according to ... who presented the findings at the Seattle conference. ...
(Date:8/22/2014)... discoveries in basic and clinical research and technological ... a complex offensive spanning multiple fronts. , Work ... could help find new and more selective therapies ... targets a specific enzyme overexpressed in certain cancersand ... brain tumours. , Chemistry professor Christopher Cairo and ...
(Date:8/22/2014)... consumers will finally be able to purchase fuel cell ... zero-emissions vehicles, most of the cars will run on ... contributes to global warming. , Now scientists at Stanford ... an ordinary AAA battery to produce hydrogen by water ... two electrodes that split liquid water into hydrogen and ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3
... to provide a detailed picture of how and when ... in animals, including humans. The evolutionary origins of ... of phylogenetic relationships among the earliest opsin-possessing animals. ... and colleagues at NUI Maynooth performed a computational analysis ...
... , Inc. (OTCBB: BLFS), a leading developer, manufacturer and ... and cryopreservation freeze media for cells and ... announced the Company,s novel biopreservation technology is being used ... it the leading choice in the emerging, high growth ...
... you fitter than ever mentally fit. In a ... of high-intensity interval training. At the end, their cognitive functions ... had improved significantly, says Dr. Martin Juneau, director of ... to people who exercise, they say they feel sharper. Now ...
Cached Biology News:BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies 2BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies 3BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies 4Exercise is smart for your heart - and makes you smarter 2
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Anti-Mouse Qa.m7, Ascites (Clone 5035-50.1) (mouse IgM)...
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
Biology Products: